ParkCell AB was formed to exploit the research developments of Dr. Mats J. Olsson of Uppsala, Sweden and Dr. Stig Rehncrona of Lund, Sweden. The research and development behind our product development is fully accomplished by members of our team and goes back almost 30-years in time.

Dr. Olsson has successfully transplanted autologous cultured melanocytes and keratinocytes onto patients with various skin disorders. He has developed an in vitro method of culturing and enriching a skin biopsy to produce a melanocyte-rich ultra-thin, epidermal sheets or free and pure cell-suspensions which is then transplanted to the same patient. The results have been very positive for these patients, and long-term follow-up has demonstrated that these cells actively grow and remain viable for years. Based on this research and clinical applications, we have developed processes to purify and multiply L-dopa/dopamine producing cells of the same origin as the cells that get loss in in the development of Parkinson’s disease. We believe that these cells have a good chance to restore the endogens production of neurotransmitters for PD patients if these cells are injected into the brain.

Dr. Rehncrona has successfully transplanted allogeneic cells harvested from fetal tissue in both Parkinson’s patients and patients that has lost their dopaminergic signaling due to exposure to toxic chemicals. It has been proven that we can achieve an improvement of motoric functions and a long-term survival of active cells. Although this is a functional treatment, it can never become a conventional treatment due to lack of compatible donor tissue and other risks involved when non-self tissue is being used.

With our novel methods we can circumvents all of these problems and ensure a high yield of pure and safe cells.

Our cells are very closely related to the cells in the brain that are lost in Parkinson’s Disease. These cells have the same origin and produce substances needed to restore motor function, and substances that seem protective of the surrounding brain tissue. Based on the research and development work at  ParkCell’s, it is believed that these cells can be enriched, be tied into a matrix and then transplanted into the PD patient’s brain. These cells can be frozen in a special freezer medium, where they remain viable for several years, and shipped around the world for transplantation.

It is believed that these cells in PD patients will accomplish the following:

  • Restore L-dopa/dopamine production
  • Result in a high expression of Tyrosinase, Tyrosine Hydroxylase and 6(R)L-erythro 5,6,7,8, tetrahydrobiopterin (an important co-factor when synthesizing catecholamines via TH and Tyrosinase)
  • Restore protection against free-radicals
  • Restore the lost buffering capacity that melanin and the melanosomes ensure
  • Ensure a communication to neighboring cells via the axonal transport of TH/Tyrosinase/L-dopa/melanin containing vesicles throughout the dendrites and transfer to surrounding cells/tissue

In addition to the potential to treat PD patients with new autologous cells, ParkCell has also acquired data from Dr. Olsson earlier academic research of biological markers of predicting PD, and will examine the potential to provide screening services for individuals to determine their biological predisposition to develop Parkinson’s Disease in the future.